We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Microfluidic Cassette Analyses Genes and Proteins

By LabMedica International staff writers
Posted on 14 Sep 2010
Print article
A device that quickly identifies genes and proteins in body fluids has been developed that could make a vital difference to the trauma patients doctors treat.

A new method to isolate cells from patient samples is under development and analyzing them will help predict outcomes after severe trauma The technology, called a microfluidic cassette, allows precise analysis of very small volumes of fluids and can be used to study patients' genes and proteins.

Knowing the genomic signature of a cell population can help doctors diagnose diseases and may allow them to predict how individual patients will respond to trauma and what treatments to order. The approach also could be used with patients who have cancer or other conditions. Scientists at the University of Florida, (UF; Gainesville, FL, USA), developed and tested the cassette to isolate neutrophils, the first type of white blood cell on the scene of an infection, and to analyze the proteins they produce. A sample of fluid, such as blood or urine, is pumped through the device, which is laced with antibodies that capture the individual cells.

Testing showed the device yielded pure samples of neutrophils, and their gene expression pattern was consistent with results from tests performed in previous studies. The team was able to identify 63 genes that are differentially expressed. The genes in question regulate functions of the immune system. Patients, whose expression of these genes is abnormal, are less likely to return to their normal immune function within days of trauma, as most patients do. This leaves them more vulnerable to infections and a myriad of related complications.

Lyle L. Moldawer, Ph.D., a professor at UF said, "What is so powerful about this technique is that you can isolate any cell population quickly and efficiently at the bedside. In this case we isolated blood neutrophils, but we' have also isolated T cells, mixed leukocytes, monocytes. Theoretically, you can isolate any cell population, under any disease, and rapidly get nucleic acids to produce a genomic signature."

Kenneth Kotz, Ph.D., a research fellow at Massachusetts General Hospital (Boston, MA, USA) added, "We are getting 100 ng of ribonucleic acid (RNA) from 0.15 mL of blood and we're doing it all in 30 minutes. No one has really ever been able to do this for neutrophils. No one has been able to demonstrate the speed and the sample quality with these small blood volumes." The results of the study were published September 2010 in Nature Medicine.

Related Links:
University of Florida
Massachusetts General Hospital


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
ACTH Assay
ACTH ELISA
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.